Authors

Carrie Horton, MS, CGC

Latest:

Horton on Addressing the Equity Gap of Genetic Testing in Cancer Care

Carrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.

Pavani Chalasani, MD, MPH

Latest:

Dr Chalasani on the Potential Utility of Eftilagimod Alpha in HER2–/HER2-Low Breast Cancer

Pavani Chalasani, MD, MPH, discusses the potential clinical significance of the AIPAC-003 trial of eftilagimod alpha in HER2–/HER2-low breast cancer.

Angel Qin, MD

Latest:

Dr Qin on Areas of Active and Future Investigation in NSCLC

Angel Qin, MD, discusses several areas of active investigation in non–small cell lung cancer, and highlights questions necessitating future research in this disease space.

Shari Mycek

Latest:

Real-World Treatment Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations in MCL

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

Sailaja Kamaraju, MD

Kathleen O’Brien

Latest:

The Desire to Always Do More

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

Marlana M. Orloff, MD, Thomas Jefferson University Hospital

Latest:

Future Management of Uveal Melanoma

The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.

Annie Im, MD, FASCO

Latest:

Dr Annie Im: How to Treat Acute Myeloid Leukemia in 2024

Annie Im, MD, FASCO, University of Pittsburgh/UPMC Hillman Cancer Center, discusses the various modern approaches for the treatment of patients with acute myeloid leukemia.

Haeseong Park, MD, MPH

Latest:

Dr Park on the Combo of Epacadostat and Chemoradiation in Advanced Rectal Cancer

Haeseong Park, MD, MPH, discusses the rationale for combining epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

Gordana Vunjak-Novakovic, PhD, BS, MS

Latest:

Dr. Vunjak-Novakovic on the Clinical Need for Personalizing Cancer Care

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

Antonio Martin Jimenez Jimenez, MD

Latest:

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.

Debra L. Richardson, MD, FACS, FACOG

Latest:

Dr Richardson on the Safety of Upifitamab Rilsodotin in Platinum-Resistant Ovarian Cancer

Debra L. Richardson, MD, FACS, FACOG, discusses the safety profile of upifitamab rilsodotin in the phase 1/2 UPLIFT trial of patients with ovarian cancer.

Monica M. Mita, MD

Latest:

Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Sanjay Popat, BSc, MBBS, FRCP, PhD

Latest:

Dr Popat on the Efficacy and Safety Profiles of Zongertinib in HER2-Mutated NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses data that have been reported with zongertinib in patients with HER2-mutated NSCLC.

Jin Qian, PhD

Latest:

Dr Qian on Preclinical Data for a CXCR4 Partial Agonist Plus Anti–PD-1 Therapy in Gastric Cancer.

Jin Qian, PhD, discusses preclinical findings for CXCR4 partial agonist in combination with anti–PD-1 therapy in advanced gastric cancer.

Suchita Pakkala, MD

Latest:

Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer Treatment

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

Katherine Clifton, MD

Latest:

Imlunestrant Clinical Data: Insights From the EMBER and EMBER-3 Trials

Dr. Clifton and Dr. Gandhi review the EMBER trial program, discussing study designs, key findings from phase 1b and EMBER-3 trials of imlunestrant-based combinations, and insights into efficacy, safety, and subgroup outcomes in estrogen receptor–positive/HER2-negative (ER+/HER2–) advanced breast cancer (ABC).

Sapna Patel, BA, MD

Latest:

Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

Doctors discuss the effectiveness of different treatment combinations for patients with BRAF-mutated metastatic melanoma and brain metastases, highlighting that consideration of patient preferences is essential in making treatment decisions.

Jathin Bandari, MD

Latest:

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Fortunato Ciardiello, MD, PhD, University of Campania

Latest:

Optimizing Treatment Strategies in Relapsed/Refractory Metastatic CRC